drugset / Trial / NCT04199598

Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.

NCT04199598

Phase 1 Terminated 25 enrolled AstraZeneca Parexel · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The study is intended to assess the relative bioavailability of 2 different abediterol nebulised formulations (test) and the dry powder formulation (reference). The study results will provide information on the pharmacokinetic (PK) profile following use of the 3 devices to be used in further clinical development.

Timeline

Start
2020-01-28
Primary completion
2020-04-03
Completion
2020-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Abediterol Small molecule 2.4 ug Inhaled
Subject Abediterol Small molecule 2.5 ug Inhaled
Subject Abediterol Small molecule 4.8 ug Inhaled